P D Lister

Summary

Affiliation: Creighton University
Country: USA

Publications

  1. ncbi Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa
    P D Lister
    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Antimicrob Agents Chemother 42:1610-9. 1998
  2. ncbi Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae
    Philip D Lister
    Center for Research in Anti Infectives and Biotechnology Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA
    Postgrad Med 120:46-52. 2008
  3. ncbi Carbapenems in the USA: focus on doripenem
    Philip D Lister
    Creighton University School of Medicine, Department of Medical Microbiology and Immunology, 2500 California Plaza, Omaha, NE 68178, USA
    Expert Rev Anti Infect Ther 5:793-809. 2007
  4. ncbi Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs
    Philip D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
    J Antimicrob Chemother 57:999-1003. 2006
  5. ncbi The role of pharmacodynamic research in the assessment and development of new antibacterial drugs
    Philip D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
    Biochem Pharmacol 71:1057-65. 2006
  6. ncbi Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa
    Philip D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Clin Infect Dis 40:S105-14. 2005
  7. ncbi Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms
    Philip D Lister
    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
    Clin Microbiol Rev 22:582-610. 2009
  8. ncbi Chromosomally-encoded resistance mechanisms of Pseudomonas aeruginosa: therapeutic implications
    Philip D Lister
    Department Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Am J Pharmacogenomics 2:235-43. 2002
  9. ncbi Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae
    Philip D Lister
    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, Nebraska 68178, USA
    Diagn Microbiol Infect Dis 44:43-9. 2002
  10. ncbi Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin
    P D Lister
    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Antimicrob Agents Chemother 43:882-9. 1999

Research Grants

  1. Novel Targets for Treatment of Pseudomonas aeruginosa
    Philip Lister; Fiscal Year: 2007

Detail Information

Publications22

  1. ncbi Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa
    P D Lister
    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Antimicrob Agents Chemother 42:1610-9. 1998
    ..This positive interaction appears to be due in part to the ability of aztreonam to protect cefepime from extracellular cephalosporinase inactivation. Clinical evaluation of this combination is warranted...
  2. ncbi Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae
    Philip D Lister
    Center for Research in Anti Infectives and Biotechnology Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA
    Postgrad Med 120:46-52. 2008
    ..The decreased efficacy of both levofloxacin doses against the double parC and gyrA/B mutants highlights the importance of preventing the development and spread of double mutants...
  3. ncbi Carbapenems in the USA: focus on doripenem
    Philip D Lister
    Creighton University School of Medicine, Department of Medical Microbiology and Immunology, 2500 California Plaza, Omaha, NE 68178, USA
    Expert Rev Anti Infect Ther 5:793-809. 2007
    ....
  4. ncbi Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs
    Philip D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
    J Antimicrob Chemother 57:999-1003. 2006
    ..In this study, the efficacy of levofloxacin/imipenem was further evaluated against a panel of characterized P. aeruginosa strains that lacked susceptibility to one or both drugs in the combination...
  5. ncbi The role of pharmacodynamic research in the assessment and development of new antibacterial drugs
    Philip D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
    Biochem Pharmacol 71:1057-65. 2006
    ..This review will focus on the tools, methods, and strategies used to characterize the pharmacodynamics of antibacterial agents and aide in their development for clinical use...
  6. ncbi Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa
    Philip D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Clin Infect Dis 40:S105-14. 2005
    ..aeruginosa strains, even when subpopulations resistant to both drugs are present. Further studies are warranted to evaluate the use of this combination against strains with established resistance to either or both drugs...
  7. ncbi Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms
    Philip D Lister
    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
    Clin Microbiol Rev 22:582-610. 2009
    ..aeruginosa, it is clear that we have much to learn about how this resourceful pathogen coregulates different resistance mechanisms to overcome the antibacterial challenges it faces...
  8. ncbi Chromosomally-encoded resistance mechanisms of Pseudomonas aeruginosa: therapeutic implications
    Philip D Lister
    Department Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Am J Pharmacogenomics 2:235-43. 2002
    ..Since the standard combination of an aminoglycoside and a beta-lactam has been shown to be ineffective in preventing the emergence of some resistance problems, the search for more effective combinations must be a priority...
  9. ncbi Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae
    Philip D Lister
    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, Nebraska 68178, USA
    Diagn Microbiol Infect Dis 44:43-9. 2002
    ..6 and 3.2 micro g/ml, viable counts never fell below 10(4) cfu/ml. The rapid killing and eradication of these pneumococci by the 750 mg dose warrant the clinical evaluation of this new dose in the treatment of pneumococcal infections...
  10. ncbi Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin
    P D Lister
    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Antimicrob Agents Chemother 43:882-9. 1999
    ..aeruginosa infections, particularly in immunocompromised patients. For piperacillin-tazobactam, induction is not an issue in the context of treating this pathogen...
  11. ncbi Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
    P D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Antimicrob Agents Chemother 43:1118-23. 1999
    ..These data corroborate clinical data and suggest that trovafloxacin has a pharmacodynamic advantage over ciprofloxacin and ofloxacin against S. pneumoniae in relation to its enhanced antipneumococcal activity...
  12. ncbi Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
    P D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA
    J Antimicrob Chemother 43:79-86. 1999
    ..Furthermore, these data suggest that the minimum AUIC required for clinical efficacy against and eradication of S. pneumoniae with levofloxacin and ciprofloxacin may be well below the 125 SIT(-1) x h identified by other studies...
  13. ncbi Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model
    P D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA
    Clin Infect Dis 32:S33-8. 2001
    ..These in vitro observations warrant the clinical evaluation of moxifloxacin in the treatment of staphylococcal infections...
  14. ncbi Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae
    P D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
    J Antimicrob Chemother 47:811-8. 2001
    ..pneumoniae strains when maximum doses were simulated in an IVPM...
  15. ncbi Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication
    Philip D Lister
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska 68178, USA
    Antimicrob Agents Chemother 46:69-74. 2002
    ..In addition, similar studies with higher peak/MIC ratios are needed to better define the impact of AUC/MIC ratios and peak/MIC ratios on the antipneumococcal pharmacodynamics of fluoroquinolones...
  16. ncbi Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin
    Daniel J Wolter
    Center for Research in Anti Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA
    Antimicrob Agents Chemother 51:2997-3000. 2007
    ..However, ampD complementation restored wild-type levels of ampC expression and ceftazidime susceptibility, suggesting alternative mechanisms of ampC regulation...
  17. ncbi Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype
    Daniel J Wolter
    Center for Research in Anti Infectives and Biotechnology, Creighton University School of Medicine, Omaha, NE 68178, USA
    J Antimicrob Chemother 64:294-300. 2009
    ..In this study, hypersusceptible P. aeruginosa isolates were analysed for changes in intrinsic resistance mechanisms to explain the observed phenotype...
  18. ncbi AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump
    Daniel J Wolter
    Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, Nebraska 68178, USA
    Antimicrob Agents Chemother 49:4763-6. 2005
    ..Furthermore, hypersusceptibility is not caused by changes in expression of the outer membrane porin, OprD...
  19. ncbi Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital
    Daniel J Wolter
    Center for Research in Anti-Infectives and Biotechnology, Creighton University School of Medicine, Omaha, NE, USA
    Diagn Microbiol Infect Dis 50:43-50. 2004
    ..Instead, resistance to these two agents seemed to arise through independent mutational events...
  20. ncbi Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance
    Daniel J Wolter
    Department of Medical Microbiology and Immunology, Center for Research in Anti-Infectives and Biotechnology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
    FEMS Microbiol Lett 236:137-43. 2004
    ..This observation does not explain the observed decrease in transcriptional expression. This is the first report of carbapenem resistance occurring through insertional inactivation of the oprD gene by IS elements...
  21. ncbi Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase
    Chonghua Li
    School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA
    J Antimicrob Chemother 53:297-304. 2004
    ..aeruginosa; clavulanate had synergy with the antibacterial activity of ticarcillin at low concentration, but had no effect on ticarcillin at high concentration due to AmpC induction by clavulanate...
  22. ncbi Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones
    Philip D Lister
    J Antimicrob Chemother 51:199-202. 2003

Research Grants2

  1. Novel Targets for Treatment of Pseudomonas aeruginosa
    Philip Lister; Fiscal Year: 2007
    ....